Self-funded employer groups face an overwhelming number of challenges in 2023 and beyond when tasked with controlling pharmacy costs, including an emerging anti-obesity pipeline,…
Spend and trend rise in 2022 forecasted to continue (DALLAS, TX) – Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the release of…
Highlights plan sponsors’ strategies to address changing environment (DALLAS, TX) – Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the launch of…
(DALLAS, TX) – Pharmaceutical Strategies Group (PSG), an EPIC company, is pleased to announce the release of its annual Trends in Specialty Drug Benefits report. Delivering visibility…
Revolutionary Drug Management Reporting Tool Offers Powerful User Insights Dallas, TX (January 23, 2023) – Artemetrx®, the industry’s most preeminent platform for integrated drug cost management,…
Republished with Permission from AIS Health The FDA recently approved the first novel long-acting granulocyte colony-stimulating factor (G-CSF) in more than 20…
Customer Satisfaction Report Dives into Current PBM Sentiment by Plan Sponsors DALLAS, TX – Pharmaceutical Strategies Group (PSG), an EPIC company, has released its 25th annual…